Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer Discontinues Phase III Sutent Trial | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Pfizer Discontinues Phase III Sutent Trial

Pfizer has discontinued the SUN 1170 Phase III study of Sutent (sunitinib malate) in advanced hepatocellular carcinoma (HCC), or liver cancer.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer has discontinued the SUN 1170 Phase III study of Sutent (sunitinib malate) in advanced hepatocellular carcinoma (HCC), or liver cancer. The decision follows a review by the independent Data Monitoring Committee (DMC) that showed a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm. Also, sunitinib did not demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced liver cancer. No new or unexpected serious adverse events were observed in the trial.

“There is a great need for effective new therapies for patients with advanced liver cancer. The disappointing outcome of this trial challenges all of us to work harder to understand the complex biology of this disease. The result of this trial in hepatocellular cancer patients does not diminish our confidence in Sutent for the treatment of patients with renal cell cancer and GIST. We are committed to patient safety and are working with investigators to better understand these trial results and their implications for clinical practice,” said Dr. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs for Pfizer’s Oncology Business Unit. “We continue to study the potential role of Sutent in the treatment of various types of cancer in late-stage trials.”

Sunitinib is currently approved for both gastrointestinal stromal tumors (GIST) after disease progression or intolerance to imatinib mesylate, and advanced/metastatic renal cell carcinoma (RCC).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters